Compare · BBOT vs NVO
BBOT vs NVO
Side-by-side comparison of BridgeBio Oncology Therapeutics Inc. (BBOT) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BBOT and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 293.9x BBOT ($623.2M).
- Over the past year, BBOT is down 28.3% and NVO is down 45.7% - BBOT leads by 17.3 points.
- NVO has hit the wire 8 times in the past 4 weeks while BBOT has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 7 for BBOT).
- Company
- BridgeBio Oncology Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $7.77-0.64%
- $41.01-4.51%
- Market cap
- $623.2M
- $183.15B
- 1M return
- -1.52%
- -10.44%
- 1Y return
- -28.32%
- -45.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 0
- 8
- Recent ratings
- 7
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest BBOT
- SEC Form 424B3 filed by BridgeBio Oncology Therapeutics Inc.
- SEC Form 10-Q filed by BridgeBio Oncology Therapeutics Inc.
- BridgeBio Oncology Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress
- SEC Form 4 filed by COO & Principal Financial Ofcr Elmelech Idan
- SEC Form 4 filed by President and CEO Beltran Pedro
- BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Canaccord Genuity initiated coverage on BridgeBio Oncology Therapeutics with a new price target
- SEC Form 424B3 filed by BridgeBio Oncology Therapeutics Inc.
- Chief Med & Dev Officer Ben Yong covered exercise/tax liability with 1,047 shares, decreasing direct ownership by 2% to 45,623 units (SEC Form 4) to satisfy withholding tax
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care